Allergan to Present New Data from its Eye Care Portfolio at the 2021 ASCRS
Allergan announced that it will present new data from its leading portfolio of eye care medicines at the 2021 ASCRS (American Society for Cataract and Refractive Surgery) annual meeting being held July 23-27 in Las Vegas. Presentations will include new data on AGN-190584 (pilocarpine 1.25%), an investigational presbyopia treatment, and updated analyses on Durysta (bimatoprost intracameral implant), the first and only FDA-approved dissolvable implant to reduce eye pressure in people with open angle glaucoma or high eye pressure.
“As a company, we remain committed to advancing care for difficult-to-treat eye conditions and diseases, such as presbyopia and glaucoma, that have a profound impact on daily life for millions of people,” Michael R. Robinson, MD, vice president, global therapeutic area head, eye care, AbbVie, said in a company news release. “Data presented at the 2021 ASCRS Annual Meeting will help us understand the potential for AGN-190584 to be a first-of-its-kind treatment option for those living with presbyopia, as well as augment our knowledge of DURYSTA, which has changed how physicians can care for patients with glaucoma.”
Researchers will present new data evaluating the efficacy, safety and tolerability of investigational AGN-190584 for the treatment of presbyopia, inclusive of full data results from the phase 3 GEMINI 1 study. GEMINI 1 data, in combination with data from the GEMINI 2 study, formed the basis of the AGN-190584 new drug application (NDA) currently under review with the FDA, which the agency is expected to act on by the end of 2021.
Updated analyses from the phase 3 ARTEMIS studies assessing the efficacy and duration of Durysta will also be presented. Durysta was approved by the FDA in March 2020 to reduce IOP in patients with open angle glaucoma (OAG) or high eye pressure (ocular hypertension, or OHT). Allergan has continued to collect data to further understand how Durysta can best be used to benefit patients living with glaucoma.
Details about Allergan’s presentations are as follows:
Abstract Linked to ASCRS program | Presentation Details All Times PDT |
Glaucoma | |
Session: Minimally Invasive Glaucoma Surgery (MIGS) III Sunday, July 25 2:05 – 2:10 p.m. Room: MBCR – Level 2, Lagoon F | |
Session: Minimally Invasive Glaucoma Surgery (MIGS) III Sunday, July 25 2:10 – 2:15 p.m. Room: MBCR – Level 2, Lagoon F | |
Session: Minimally Invasive Glaucoma Surgery (MIGS) III Sunday, July 25 2:20 – 2:25 p.m. Room: MBCR – Level 2, Lagoon F | |
Presbyopia | |
Gemini 1 Phase 3: AGN-190584 Improves Intermediate Vision in Participants with Presbyopia | Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies Sunday, July 25 8:00 – 8:05 a.m. Room: MBCR – Level 2, Lagoon F |
Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies Sunday, July 25 8:05 – 8:10 a.m. Room: MBCR – Level 2, Lagoon F | |
Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies Sunday, July 25 8:10 – 8:15 a.m. Room: MBCR – Level 2, Lagoon F | |
Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies Sunday, July 25 8:15 – 8:20 a.m. Room: MBCR – Level 2, Lagoon F | |
Gemini 1 Phase 3: Safety and Efficacy of AGN-190584 in Participants with Presbyopia | Session: Presbyopia Correcting IOL Comparisons, New Treatments and Studies Sunday, July 25 8:25 – 8:30 a.m. Room: MBCR – Level 2, Lagoon F |
*ASCRS Disclaimer: All educational content of the ASCRS ASOA Annual Meeting is planned by its program committee, and ASCRS ASOA does not endorse, promote, approve, or recommend the use of any products, devices, or services.